Daxor Corp
DXR
Company Profile
Business description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.
Contact
107 Meco Lane
Oak RidgeTN37830
USAT: +1 212 330-8500
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
750
Stocks News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
A durable growth story despite GLP-1 headwinds.
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
We see regulatory risk from both the US and Chinese governments.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,968.80 | 42.20 | 0.47% |
| CAC 40 | 7,847.32 | 64.50 | 0.83% |
| DAX 40 | 25,410.84 | 229.19 | 0.91% |
| Dow JONES (US) | 52,361.58 | 146.42 | 0.28% |
| FTSE 100 | 10,767.33 | 76.97 | 0.72% |
| HKSE | 23,020.31 | 191.50 | -0.83% |
| NASDAQ | 26,169.38 | 214.04 | 0.82% |
| Nikkei 225 | 63,268.37 | 1,078.72 | 1.73% |
| NZX 50 Index | 13,680.27 | 53.66 | -0.39% |
| S&P 500 | 7,676.77 | 53.09 | 0.70% |
| S&P/ASX 200 | 8,850.10 | 40.20 | 0.46% |
| SSE Composite Index | 3,648.30 | 49.22 | -1.33% |